Hikma Pharmaceuticals USA Announces $1 Billion Investment to Expand Domestic Manufacturing and R&D

Overview of the Investment

On June 30, 2025, the Association for Accessible Medicines (AAM) acknowledged Hikma Pharmaceuticals USA’s announcement to invest $1 billion by 2030 to expand its domestic manufacturing and research and development (R&D) capabilities. This strategic investment targets facilities in Columbus and Cleveland, Ohio, as well as Cherry Hill and Dayton, New Jersey.

Significance to Sustainable Development Goals (SDGs)

This investment aligns with several United Nations Sustainable Development Goals, including:

• SDG 3: Good Health and Well-being – By enhancing the production of essential generic medicines, Hikma contributes to improving access to affordable and quality healthcare.
• SDG 9: Industry, Innovation, and Infrastructure – The expansion of manufacturing and R&D facilities promotes innovation and strengthens domestic pharmaceutical infrastructure.
• SDG 8: Decent Work and Economic Growth – The investment supports job creation and economic development in the U.S. pharmaceutical sector.
• SDG 17: Partnerships for the Goals – Collaboration between Hikma, government representatives, and AAM exemplifies effective partnerships to advance healthcare access and industry resilience.

Details of the Expansion

1. Hikma broke ground on the expansion of its manufacturing and R&D facility in Columbus, Ohio.
2. U.S. Representatives Mike Carey (OH-15) and Buddy Carter (GA-01) participated in the groundbreaking ceremony, highlighting bipartisan support.
3. Hikma’s cumulative investment in U.S.-based R&D and manufacturing exceeds $4 billion over the past 15 years.
4. The company currently has an annual domestic capacity to produce over 12 billion finished doses of more than 800 medicines.

Role of the Association for Accessible Medicines (AAM)

The AAM represents manufacturers of generic pharmaceuticals and biosimilars, bulk pharmaceutical chemicals, and related suppliers. The organization emphasizes the importance of access to safe, quality, and effective medicines, which supports SDG 3 by improving health outcomes globally.

• Generic pharmaceuticals account for 90% of prescriptions dispensed in the U.S.
• They represent only 13.1% of total drug spending, demonstrating cost efficiency and affordability.
• AAM collaborates with the U.S. Administration and Congress to promote domestic manufacturing and supply chain resilience.

About the Biosimilars Council

The Biosimilars Council, a division of AAM, focuses on enhancing patient access to biosimilar medicines, which are more affordable alternatives to brand biologic drugs. This initiative supports SDG 3 by increasing availability of effective treatments and reducing healthcare costs.

• Key areas of focus include public and health expert education, government affairs, legal affairs, and regulatory policy.
• It serves as a leading source of information on the safety and efficacy of biosimilars.

Additional Resources and Contact Information

• Read Hikma Press Release
• For media inquiries, contact: media@accessiblemeds.org
• More information about AAM: https://accessiblemeds.org/
• More information about the Biosimilars Council: https://biosimilarscouncil.org/

1. Sustainable Development Goals (SDGs) Addressed in the Article

1. SDG 3: Good Health and Well-being
   • The article discusses the expansion of manufacturing and research of generic medicines, which improves access to safe, quality, and effective medicines, directly contributing to better health outcomes.
2. SDG 9: Industry, Innovation, and Infrastructure
   • Hikma Pharmaceuticals’ $1 billion investment in domestic manufacturing and R&D supports industrial innovation and infrastructure development in the U.S.
3. SDG 8: Decent Work and Economic Growth
   • Expansion of manufacturing facilities and R&D capabilities implies job creation and economic growth in the regions mentioned (Ohio and New Jersey).
4. SDG 17: Partnerships for the Goals
   • The collaboration between Hikma, the Association for Accessible Medicines, U.S. government representatives, and Congress reflects partnerships to foster domestic manufacturing and healthcare resilience.

2. Specific Targets Under the Identified SDGs

1. SDG 3: Good Health and Well-being
   • Target 3.8: Achieve universal health coverage, including access to quality essential medicines and vaccines.
   • Target 3.b: Support the research and development of vaccines and medicines for communicable and non-communicable diseases.
2. SDG 9: Industry, Innovation, and Infrastructure
   • Target 9.2: Promote inclusive and sustainable industrialization and, by 2030, significantly raise industry’s share of employment and gross domestic product.
   • Target 9.5: Enhance scientific research, upgrade technological capabilities of industrial sectors.
3. SDG 8: Decent Work and Economic Growth
   • Target 8.2: Achieve higher levels of economic productivity through diversification, technological upgrading, and innovation.
4. SDG 17: Partnerships for the Goals
   • Target 17.16: Enhance the Global Partnership for Sustainable Development, complemented by multi-stakeholder partnerships.

3. Indicators Mentioned or Implied in the Article

1. Access to Medicines and Health Coverage
   • Percentage of prescriptions dispensed as generic medicines (mentioned as 90% in the U.S.).
   • Proportion of total drug spending on generic medicines (13.1% as mentioned).
2. Industrial and R&D Capacity
   • Investment amount in domestic manufacturing and R&D ($1 billion by 2030, $4 billion over 15 years).
   • Annual domestic production capacity (more than 12 billion finished doses of over 800 medicines).
3. Economic and Employment Indicators
   • Number and scale of manufacturing and R&D facilities expanded (Columbus, Cleveland, Cherry Hill, Dayton).
   • Job creation implied by facility expansions and investments.
4. Partnerships and Policy Engagement
   • Collaboration with government representatives and legislative bodies to foster manufacturing resilience.

4. Table of SDGs, Targets, and Indicators

Source: accessiblemeds.org